The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Tue., Dec. 6, 9:36 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #76. MEI Pharma, Inc. PWT143

Acquirer: MEI Pharma, Inc. (NASDAQ:MEIP)
Acquiree: PWT143
Details: MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has acquired exclusive worldwide rights to the investigational drug candidate PWT143 from Pathway Therapeutics, Inc., a privately held pharmaceutical company, for an undisclosed upfront payment with no future milestone or royalty obligations.

MEI Pharma is a late-stage pharmaceutical company focused on the development and commercialization of cancer therapies to improve outcomes for patients. Co.'s portfolio of drug candidates includes three clinical-stage assets, including: Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor; Voruciclib, an oral cyclin-dependent kinase 9 inhibitor; and ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex.

Open the MEIP Page at The Online Investor »

Company Name: 
MEI Pharma Inc
Website: 
www.meipharma.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding MEIP: 
3
Total Market Value Held by ETFs: 
$12.77M
Total Market Capitalization: 
$44.00M
% of Market Cap. Held by ETFs: 
29.03%
 

Open the MEIP Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree MEIP Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (2.86 out of 4)
15th percentile
(ranked lower than approx. 85% of all stocks covered)

Analysts' Target Price:
MEIP Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Drugs & Pharmaceuticals M&A - Slide 76 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.